This clinical trial is focused on studying Multiple Sclerosis, a disease that affects the brain and spinal cord, leading to a range of symptoms such as fatigue, difficulty walking, and vision problems. The study is evaluating the safety and effectiveness of a medication called fingolimod, which is taken as a capsule by mouth. Fingolimod is being compared to another treatment called interferon β-1a, which is given as an injection once a week. The purpose of the study is to understand how well fingolimod works and how safe it is for children with multiple sclerosis.

The study is designed to last for two years, during which participants will receive either fingolimod or interferon β-1a. After this period, there is an additional five-year phase where participants may continue to receive fingolimod. Throughout the study, researchers will monitor the participants’ health and any changes in their symptoms. This will help determine the long-term effects of fingolimod on aspects such as cognitive function, which involves thinking and memory, and physical and sexual development.

Participants will be randomly assigned to receive either fingolimod or interferon β-1a, and neither the participants nor the researchers will know which treatment each participant is receiving. This is known as a “double-blind” study. The study aims to provide valuable information on the potential benefits and risks of using fingolimod in young patients with multiple sclerosis, contributing to better treatment options in the future.